COMMUNIQUÉS West-GlobeNewswire

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
21/07/2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and [...]
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
21/07/2026
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- [...]
Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange
21/07/2026
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today [...]
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
21/07/2026
TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
21/07/2026
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE [...]
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
21/07/2026
750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk ACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX [...]
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting
21/07/2026
PRESS RELEASE Magnitude of EO2463-induced CD8 T-cell expansion during monotherapy statistically significantly associated with longer progression-free survival (PFS) in patients with indolent non-Hodgkin lymphoma (iNHL) [...]
Carbios reaches milestone of 100 batches at its Industrial demonstration plant and expands its licensing offering to the textile market
21/07/2026
Validation of the "Fiber-to-Fiber" biorecycling process under conditions representative of industrial operations 100 th batch 1 successfully produced at the Clermont-Ferrand demonstration plant More than 95% conversion [...]
OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
21/07/2026
Feedback from the U.S. Food and Drug Administration (FDA) supports acceleration of OMT-28’s development path directly into a pivotal Phase 3 study With the vast majority of PMD patients having no FDA-approved [...]
Carbios franchit le cap des 100 batchs produits au sein de son démonstrateur industriel et étend son offre de licences au marché textile
21/07/2026
Validation du procédé de biorecyclage « fibre-à-fibre », dans des conditions représentatives d’une exploitation industrielle 100 ème batch 1 produit avec succès au sein du démonstrateur de Clermont-Ferrand Plus de 95 % [...]
Transactions in connection with share buy-back program
21/07/2026
Company announcement no. 26 - 26 21 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
21/07/2026
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc 1 , +3% USD), with core operating income 1 flat (cc and USD) Sales growth driven by priority brands including Kisqali (+43% cc), Kesimpta [...]
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
21/07/2026
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the [...]
Park Dental Partners Announces Dates for Second Quarter 2026 Earnings Release and Conference Call
20/07/2026
MINNEAPOLIS, July 20, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, today announced that it will report its financial results for the quarter ended June 30, [...]
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
20/07/2026
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced [...]
UPDATE: Conceivable Life Sciences Strengthens Senior Leadership Team to Support IVI RMA Partnership and U.S. Launch
21/07/2026
Julie O'Shaughnessy named President, Vincent Payet named SVP of Commercial Operations & Partner Success to support AURA's US commercial launch NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Conceivable Life Sciences, [...]
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
20/07/2026
First patient dosed in Phase 3 LUTEON 1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is the first Phase 3 study of a CAIX 2 -targeted radiopharmaceutical therapy in [...]
Conceivable Life Sciences Strengthens Senior Leadership Team to Support IVI RMA Partnership and U.S. Launch
20/07/2026
Julie O'Shaughnessy named President, Vincent Payet named SVP of Clinical Operations & Partner Success to support AURA's US commercial launch NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Conceivable Life Sciences, the [...]
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/07/2026
SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery [...]

Pages